Ribas Antoni 4

What Happened On June 11, 2026, Antoni Ribas, a member of the board of directors of Arcus Biosciences, was granted 5,700 restricted stock units (RSUs) and a derivative award covering 16,900 shares (an option-like award). Both grants were issued at $0.00 per share (no cash paid). This was an award/compensation grant, not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-06-11; Form 4 filed 2026-06-12 (appears timely).
• Grants: 5,700 RSUs (A) and 16,900 derivative shares (A) at $0.00 per share.
• Post-transaction total holdings: not specified in the provided filing excerpt.
• Footnotes:
  • F1 (RSUs): Vest in full on the earlier of June 11, 2027 or the next annual meeting; vesting accelerates on a change in control.
  • F2 (derivative/option): Vests in full on the earlier of June 11, 2027 or the next annual meeting; becomes vested/exercisable on a change in control.
• No indication of tax withholding, sale, or cashless exercise in this filing.

Context RSUs convert into common shares when they vest; derivative awards here function like options that vest by the listed date or on certain corporate events. Because these are compensation grants to a director (not purchases or sales), they are routine and do not by themselves signal buying or selling intent. Vesting schedules and change‑in‑control acceleration affect when the director could actually acquire or sell the shares.